Airway Deposition of Extrafine Inhaled Triple Therapy in Patients with COPD: A Model Approach Based on Functional Respiratory Imaging Computer Simulations

References

• HighamA, QuinnAM, CançadoJED, SinghD. The pathology of small airways disease in COPD: historical aspects and future directions. Respir Res. 2019;20(1):49. doi:10.1186/s12931-019-1017-y30832670
   PubMed Web of Science ®Google Scholar
• KooH-K, VasilescuDM, BoothS, et al. Small airways disease in mild and moderate chronic obstructive pulmonary disease: a cross-sectional study. Lancet Respir Med. 2018;6(8):591–602. doi:10.1016/S2213-2600(18)30196-630072106
   PubMed Web of Science ®Google Scholar
• MeadJ. The lung’s “quiet zone. N Engl J Med. 1970;282(23):1318–1319. doi:10.1056/NEJM1970060428223115442364
   PubMed Web of Science ®Google Scholar
• BhattSP, SolerX, WangX, et al. Association between functional small airway disease and FEV1 decline in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2016;194(2):178–184. doi:10.1164/rccm.201511-2219OC26808615
   PubMed Web of Science ®Google Scholar
• HershCP, WashkoGR, EstéparRSJ, et al. Paired inspiratory-expiratory chest CT scans to assess for small airways disease in COPD. Respir Res. 2013;14(1):42. doi:10.1186/1465-9921-14-4223566024
   PubMed Web of Science ®Google Scholar
• CrisafulliE, PisiR, AielloM, et al. Prevalence of small-airway dysfunction among COPD patients with different GOLD stages and its role in the impact of disease. Respiration. 2017;93(1):32–41. doi:10.1159/00045247927852080
   PubMed Web of Science ®Google Scholar
• TzaniP, CrisafulliE, NicoliniG, et al. Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients. Int J Chron Obstruct Pulmon Dis. 2011;6:503–509. doi:10.2147/COPD.S2374622069361
   PubMed Web of Science ®Google Scholar
• UsmaniOS. Treating the small airways. Respiration. 2012;84(6):441–453. doi:10.1159/00034362923154684
   PubMed Web of Science ®Google Scholar
• LipworthB, ManoharanA, AndersonW. Unlocking the quiet zone: the small airway asthma phenotype. Lancet Respir Med. 2014;2(6):497–506. doi:10.1016/S2213-2600(14)70103-124899370
   PubMed Web of Science ®Google Scholar
• HillyerEV, PriceDB, ChrystynH, et al. Harmonizing the nomenclature for therapeutic aerosol particle size: a proposal. J Aerosol Med Pulm Drug Deliv. 2018;31(2):111–113. doi:10.1089/jamp.2017.139629182483
   PubMed Web of Science ®Google Scholar
• BraidoF, ScichiloneN, LavoriniF, et al. Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on Asthma. World Allergy Organ J. 2016;9(1):1–6. doi:10.1186/s40413-016-0123-226839628
   PubMed Web of Science ®Google Scholar
• LavoriniF, PedersenS, UsmaniOS; on behalf of the Aerosol Drug Management Improvement Team (ADMIT). Dilemmas, confusion, and misconceptions related to small airways directed therapy. Chest. 2017;151(6):1345–1355. doi:10.1016/j.chest.2016.07.03527522955
   PubMed Web of Science ®Google Scholar
• UsmaniOS, BarnesPJ. Assessing and treating small airways disease in asthma and chronic obstructive pulmonary disease. Ann Med. 2012;44(2):146–156. doi:10.3109/07853890.2011.58565621679101
   PubMed Web of Science ®Google Scholar
• UsmaniOS, BiddiscombeMF, BarnesPJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med. 2005;172(12):1497–1504. doi:10.1164/rccm.200410-1414OC16192448
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2020 Available from: https://goldcopd.org/gold-reports/. Accessed 95, 2020.
   Google Scholar
• De BackerJW, VosWG, VinchurkarSC, et al. Validation of computational fluid dynamics in CT-based airway models with SPECT/CT. Radiology. 2010;257(3):854–862. doi:10.1148/radiol.1010032221084417
   PubMed Web of Science ®Google Scholar
• UsmaniO, VosW, MignotB, et al. Lung deposition of extrafine inhaled corticosteroid (ICS)-containing fixed combinations drug in COPD patients using Functional Respiratory Imaging (FRI). Eur Respir J. 2018;52(suppl 62):PA1015. doi:10.1183/13993003.congress-2018.PA1015
   Web of Science ®Google Scholar
• KappelerD, SommererK, KietzigC, et al. Lung deposition of fluticasone propionate/formoterol administered via a breath-triggered inhaler. Eur Respir J. 2017;50(suppl 62):PA522.
   Google Scholar
• MüllingerB, BrandP, FischerA, et al. Intra-pulmonal deposition of two different tobramycin formulations. J Cyst Fibros. 2005;4(suppl 1):S53(abstract 198).
   Google Scholar
• De BackerW, DevolderA, PoliG, et al. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv. 2010;23(3):137–148. doi:10.1089/jamp.2009.077220109122
   PubMed Web of Science ®Google Scholar
• De MariaR, ZagnoniI, BodriaA, et al. Foster®: a high-efficiency combination metered dose inhaler with consistent particle size distribution at alternative flow rates. Comb Prod Ther. 2014;4(1–2):1–5. doi:10.1007/s13556-013-0006-6
   Google Scholar
• IwanagaT, KozukaT, NakanishiJ, et al. Aerosol deposition of inhaled corticosteroids/long-acting β2-agonists in the peripheral airways of patients with asthma using functional respiratory imaging, a novel imaging technology. Pulm Ther. 2017;3(1):219–231. doi:10.1007/s41030-017-0036-4
   Google Scholar
• HirstPH, BaconRE, PitcairnGR, SilvastiM, NewmanSP. A comparison of the lung deposition of budesonide from Easyhaler, Turbuhaler and pMDI plus spacer in asthmatic patients. Respir Med. 2001;95(9):720–727. doi:10.1053/rmed.2001.110711575892
   PubMed Web of Science ®Google Scholar
• LeachCL, KuehlPJ, ChandR, McDonaldJD. Respiratory tract deposition of HFA-beclomethasone and HFA-fluticasone in asthmatic patients. J Aerosol Med Pulm Drug Deliv. 2016;29(2):127–133. doi:10.1089/jamp.2014.119926061801
   PubMed Web of Science ®Google Scholar
• NikanderK, PrinceI, CoughlinS, WarrenS, TaylorG. Mode of breathing-tidal or slow and deep-through the I-neb Adaptive Aerosol Delivery (AAD) system affects lung deposition of (99m)Tc-DTPA. J Aerosol Med Pulm Drug Deliv. 2010;23(Suppl1):S37–S43. doi:10.1089/jamp.2009.078620373908
   PubMed Web of Science ®Google Scholar
• HullD, BlackA, VosW. Use of computational fluid dynamics (CFD) to model aerosol deposition in the lungs of patients with cystic fibrosis. J Cyst Fibros. 2018;17(suppl 3):S26. doi:10.1016/S1569-1993(18)30199-1
   PubMedGoogle Scholar
• LenneyW, EdenboroughF, KhoP, KovarikJM. Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects. J Cyst Fibros. 2011;10(1):9–14. doi:10.1016/j.jcf.2010.08.01920884302
   PubMed Web of Science ®Google Scholar
• FischerA, StegemannJ, ScheuchG, SiekmeierR. Novel devices for individualized controlled inhalation can optimize aerosol therapy in efficacy, patient care and power of clinical trials. Eur J Med Res. 2009;14(Suppl 4):71–77. doi:10.1186/2047-783x-14-s4-71
   PubMed Web of Science ®Google Scholar
• MunroS, MainM, VosW Matching delivery device to a patient’s condition: use of lung deposition modelling to optimise delivery in idiopathic pulmonary fibrosis In: Drug Delivery to the Lungs Annual Congress; 2017.
   Google Scholar
• US Food and Drug Administration. Statistical approaches to establishing bioequivalence; 2001 Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-approaches-establishing-bioequivalence. Accessed 95, 2020.
   Google Scholar
• BoniniM, UsmaniOS. The role of the small airways in the pathophysiology of asthma and chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2015;9(6):281–293. doi:10.1177/175346581558806426037949
   PubMed Web of Science ®Google Scholar
• LanghamS, LewisJ, PooleyN, et al. Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review. Respir Res. 2019;20(1):242. doi:10.1186/s12931-019-1213-931684965
   PubMed Web of Science ®Google Scholar
• Lopez-CamposJL, Carrasco-HernandezL, Quintana-GallegoE, et al. Triple therapy for COPD: a crude analysis from a systematic review of the evidence. Ther Adv Respir Dis. 2019;13:175346661988552. doi:10.1177/1753466619885522
   Web of Science ®Google Scholar
• ZhengY, ZhuJ, LiuY, et al. Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis. BMJ. 2018;363:k4388. doi:10.1136/bmj.k438830401700
   PubMed Web of Science ®Google Scholar
• BoniniM, UsmaniOS. The importance of inhaler devices in the treatment of COPD. COPD Res Pract. 2015;1(1):1–9. doi:10.1186/s40749-015-0011-0
   Google Scholar
• SinghD, CorradiM, SpinolaM, et al. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide. Int J COPD. 2017;12:2917–2928. doi:10.2147/COPD.S146822
   Google Scholar
• PapiA, VestboJ, FabbriL, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084. doi:10.1016/S0140-6736(18)30206-X29429593
   PubMed Web of Science ®Google Scholar
• SinghD, PapiA, CorradiM, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963–973. doi:10.1016/S0140-6736(16)31354-X27598678
   PubMed Web of Science ®Google Scholar
• VestboJ, PapiA, CorradiM, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389(10082):1919–1929. doi:10.1016/S0140-6736(17)30188-528385353
   PubMed Web of Science ®Google Scholar